Business Comment: Fisons can't afford to be too choosy
Wednesday 19 April 1995
That radical change was on the way was obvious the moment Mr Wallis became chief executive in September. Having no experience of pharmaceuticals, but having been part of the team that turned Bowater from paper to packaging, he brought with him no preconceived notions about the industry.
That became clear last month, when the company announced the £202m sale of Fisons' research and development arm to Astra of Sweden. R&D has always been seen as the beating heart of any self-respecting drugs operation, delivering the innovative compounds that will become the billion-pound earners of the future. To sell it seemed like an admission that the company as it stood had no viable future.
The merger of Glaxo and Wellcome has thrown into stark contrast the ballooning cost of maintaining such operations. Together, the two companies spent £1.2bn last year on their teams of researchers and hi-tech research establishments on both sides of the Atlantic. That is set to be savagely pruned by the Glaxo management, which has targeted lower costs as a key factor in making the merger work. Even so the amount Fisons had to spend was peanuts by comparison. Glaxo's actions have also rammed home that delivering low-cost medicines, rather than developing new wonder drugs at any cost, will be the name of the game in the last years of the 20th century.
Mr Wallis came to the view that what is true for the giants applies even more for a relative minnow like Fisons. Having hawked it around every pharmaceuticals group worth the name in Europe and beyond, he has hit on Medeva to put theory into practice. Medeva has come from almost nowhere since former Glaxo chief executive Bernard Taylor boarded the former Medirace five years ago. Despite a profits warning that halved the value of the shares at one stage in 1993, the shares more than doubled in that period even before the latest takeover speculation. The company's success is based on buying or licensing, rather than developing, low-cost rivals to branded products from market leaders.
A marriage of Medeva with Fisons looks perfect on a number of counts. The former's portfolio of drugs would allow Fisons' European sales force to be adequately used, given the lack of a drugs pipeline with the sale of the R&D operation. Analysts also believe that a bid at the rumoured price of £3 would result in Fisons seeing earnings enhanced by around 5 per cent. Any takeover is also likely to see Medeva management taking an important role in any operation, giving Fisons a much-needed injection of new talent.
On the face of it, then, Medeva has all the right ingredients to put Fisons back on track. Not all is sweetness and light, however. Medeva's main growth still comes essentially from methylphenidate, a compound to control hyperactivity in children that is mainly marketed in the US, while the profit warning and recent legal actions suggest management has lost its footing recently. But then a company with as desperate a need for a partner as Fisons cannot afford to be too choosy.
- 1 10 ways we damage our teeth – without realising
- 2 Fifa corruption arrests: Nike reported to be 'multinational sportswear company' at centre of bribery claims over Brazil shirt deal
- 3 Facebook Messenger sends 'creepily' precise location data, as revealed by Marauders Map Chrome extension
- 4 Bahar Mustafa: Goldsmiths Students' Union diversity officer to keep her job after vote of no confidence petition fails
- 5 Photo of wedding guest proposing to girlfriend in front of bride and groom goes viral
Hopes raised for treatment of severe amnesia after scientists retrieve lost memory – using light
Playboy model April Summers speaks out about being a victim of a voyeuristic sex crime
Poorest part of London is wealthier than the richest parts of Northern Ireland and Wales
British tourists complain that impoverished boat migrants are making holidays 'awkward' in Kos
How to live to be really old
EU referendum: David Cameron's rules are a 'democratic disgrace', says French-born Scottish politician set to be denied a vote
SNP fury as HS2 finds 'no business case' for taking fast train service to Scotland
Australian man punched in the face for defending Muslim women from abuse on train
A nation of inequality: How the UK is failing to feed its most vulnerable people
David Starkey 'tells Amal Clooney to shut up and stop over-promoting human rights'
EU referendum: David Cameron to deny EU migrants and under-18s the chance to vote
iJobs Money & Business
£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...
£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...
£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...